Recombinant Salmonella enteria serovar Pullorum, (S. Pullorum), as well as preparation method and application thereof

The invention discloses recombinant S. Pullorum, as well as a preparation method and an application thereof, belonging to the technical field of animal bacterial gene engineering. The name of the recombinant S. Pullorum is S. Pullorum C79-13deltacrpdeltaasd(pYA3493-HN), the preservation number is CC...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	CHENG XIANGCHAO, HE LEI, JIA YANYAN, LIAO CHENGSHUI, ZHANG CHUNJIE, WANG YANG, ZHAI CHONGKAI, LI JING, YU CHUAN, WU TINGCAI, YU ZUHUA, LI YINJU
Format:	Patent
Sprache:	eng
Schlagworte:	BEER BIOCHEMISTRY CHEMISTRY COMPOSITIONS THEREOF CULTURE MEDIA ENZYMOLOGY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY MICROBIOLOGY MICROORGANISMS OR ENZYMES MUTATION OR GENETIC ENGINEERING PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES PROCESSES USING MICROORGANISMS PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS SPIRITS VINEGAR WINE
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The invention discloses recombinant S. Pullorum, as well as a preparation method and an application thereof, belonging to the technical field of animal bacterial gene engineering. The name of the recombinant S. Pullorum is S. Pullorum C79-13deltacrpdeltaasd(pYA3493-HN), the preservation number is CCTCC NO:M 2015305, the newcastle diseases virus protective antigen gene-HN gene expressed by the recombinant S. Pullorum is the important immunogenic gene segment for the newcastle diseases virus, and has good immune protection. The recombination strain derives from the S. Pullorum standard strain C79-13, completely reserves the immune efficacy of C79-13 for S. Pullorum, has weaker toxicity than that of C79-13, has good bio-safety, and can simultaneously provide protection aiming at S. Pullorum and newcastle disease pathogenes. Meanwhile, the recombinant strain contains no resistance markers, and completely accords with the requirements on the bio-safety of vaccines.